Research programme: chimeric antigen receptor activated killer cell therapies - CHA Biotech/Sorrento

Drug Profile

Research programme: chimeric antigen receptor activated killer cell therapies - CHA Biotech/Sorrento

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Sorrento Therapeutics
  • Developer CHA Bio & Diostech; Sorrento Therapeutics
  • Class Cell therapies; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Infections

Most Recent Events

  • 02 Aug 2016 Sorrento and CHA Biotech agree to co-develop CAR-AKC cell therapies for Cancer and Infections
  • 02 Aug 2016 Preclinical trials in Cancer in South Korea (Parenteral) before August 2016
  • 02 Aug 2016 Preclinical trials in Infections in South Korea (Parenteral) before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top